Mehmet Bilen MD
- Department of Hematology and Medical Oncology
Associate Professor
- (404) 778-3693
- mehmet.a.bilen@emory.edu
- Winship faculty profile
- @bilenma
-
Winship Cancer Institute of Emory University
1365B Clifton Rd NE, Suite B400, Office 4212
Overview
A board certified medical oncologist, Dr. Bilen is actively involved in clinical research and patient care in the area of genitourinary cancers. He serves as director of the Genitourinary Medical Oncology Program at Winship Cancer Institute of Emory University. He works closely with the Fellowship Program of the Department of Hematology and Medical Oncology by educating fellows on genitourinary oncology. He also serves on the Winship Clinical and Translational Review Committee.
Dr. Bilen is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute. He holds professional memberships with American Association for Cancer Research and American Society of Clinical Oncology.
Dr. Bilen received his MD from Hacettepe University Faculty of Medicine in Ankara, Turkey. He completed a postdoctoral fellowship in Molecular Pathology and a clinical fellowship in Hematology/Oncology at UT MD Anderson Cancer Center in Houston, Texas. His postgraduate medical education also included residency training at Baylor College of Medicine in Houston, Texas.
As a postdoctoral fellow at UT MD Anderson Cancer Center, Dr. Bilen worked with Dr. Sue-Hwa Lin on developing biomarkers and therapeutic strategies that can be applied in clinical settings to promote early detection and to improve treatment options for prostate cancer bone metastasis. He focused on the role of cadherin-11 in prostate cancer bone metastasis and generating monoclonal antibodies that inhibited that metastasis. He showed that inhibition of cell adhesion by a cadherin-11 antibody thwarts prostate cancer bone metastasis and monotherapy using a cadherin-11 antibody is a suitable option for prevention.
Dr. Bilen continued to focus on genitourinary malignancies after becoming a clinical fellow at UT MD Anderson Cancer Center where he worked on several projects in clinical and translational research. In 2015, he was selected to participate in the AACR/ASCO Vail workshop.
Dr. Bilen has published a number of peer-reviewed original papers and reviews in leading journals including Cancer Research, Molecular Cancer Research, FASEB J, Journal of Pathology, Cancer and Clinical and Experimental Metastasis and has authored or co-authored several abstracts for presentations at professional meetings.
Academic Appointment
- Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
Education
Degrees
- MD from Hacettepe University, Ankara
Research
Publications
-
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration.
Prostate Cancer Prostatic Dis Volume: 28 Page(s): 378 - 384
06/01/2025 Authors: Zengin ZB; Henderson NC; Park JJ; Ali A; Nguyen C; Hwang C; Barata PC; Bilen MA; Graham L; Mo G -
Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer.
Prostate Cancer Prostatic Dis Volume: 28 Page(s): 419 - 426
06/01/2025 Authors: Broderick A; Pan E; Li J; Chu A; Hwang C; Barata PC; Cackowski FC; Labriola M; Ghose A; Bilen MA -
Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patients in the USA.
J Comp Eff Res Page(s): e250023
05/09/2025 Authors: Lowentritt B; Bilen MA; Khilfeh I; Rossi C; Du S; Kinkead F; Diaz L; Pilon D; Ellis L; Shore ND -
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma.
Cancer Discov Volume: 15 Page(s): 948 - 968
05/02/2025 Authors: Hugaboom MB; Wirth LV; Street K; Ruthen N; Jegede OA; Schindler NR; Shah V; Zaemes JP; El Ahmar N; Matar S -
Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10).
Urol Oncol Volume: 43 Page(s): 330.e1 - 330.e9
05/01/2025 Authors: Siefker-Radtke AO; Huddart RA; Bilen MA; Balar A; Castellano D; Sridhar SS; De Giorgi U; Penkov K; Vasiliev A; Peer A -
Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes.
Am J Clin Pathol Volume: 163 Page(s): 618 - 628
04/19/2025 Authors: Case KB; Martini DJ; Dababneh MN; Bidot S; Nazha B; Brown J; Joshi S; Narayan V; Parihar V; Saeed F -
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.
Eur Urol Oncol Volume: 8 Page(s): 258 - 262
04/01/2025 Authors: Jindal T; Jiang C; Alhalabi O; Nizam A; Nguyen C; Talukder R; Bakaloudi D; Davidsohn M; Freeman D; Glover M -
A multi-perspective study assessing Black and African American participation barriers in prostate cancer clinical trials.
Future Oncol Volume: 21 Page(s): 967 - 973
04/01/2025 Authors: Leger P; Frencher S; Nauseef JT; Jones B; Bilen MA; Brown A; Ullah A; McDevitt S; Tsao C-K -
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes.
Prostate Cancer Prostatic Dis Volume: 28 Page(s): 129 - 137
03/01/2025 Authors: Zorko NA; Makovec A; Elliott A; Kellen S; Lozada JR; Arafa AT; Felices M; Shackelford M; Barata P; Zakharia Y -
Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial.
Nat Cancer Volume: 6 Page(s): 432 - 444
03/01/2025 Authors: Bilen MA; Vo BT; Liu Y; Greenwald R; Davarpanah AH; McGuire D; Shiradkar R; Li L; Midya A; Nazha B -
Diuresis During 18F-Flotufolastat (rhPSMA-7.3) PET/CT Improves Recurrence Detection After Prostatectomy: A Prospective Phase II Trial.
J Nucl Med Volume: 66 Page(s): 230 - 237
02/03/2025 Authors: Lawal IO; Mushtaq A; Jani AB; Rupji M; Dhere VR; Patel SA; Bilen MA; Patel PR; Sebastian NT; Switchenko JM -
Characteristics, Treatment, and Outcomes of Primary Urethral Cancer: A Multicenter Review Over Two Decades.
Clin Genitourin Cancer Volume: 23 Page(s): 102276
02/01/2025 Authors: Hopkins BD; Qian DC; Xu KM; McCook-Veal A; Switchenko J; Hartsell LM; Cimmino CB; Joshi SS; Narayan V; Master VA -
Real-World Outcomes in Patients with Advanced Penile Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Single Institution Experience.
J Immunother Precis Oncol Volume: 8 Page(s): 1 - 10
02/01/2025 Authors: Zhuang TZ; Goyal S; Case KB; Olsen TA; Vemuru S; Yildirim A; Goswamy RV; Brown JT; Carthon BC; Kucuk O -
Treatment patterns for patients with BRCA1/2-positive metastatic castration-resistant prostate cancer.
Oncologist Volume: 30
01/17/2025 Authors: Bilen MA; Khilfeh I; Rossi C; Morrison L; Diaz L; Hilts A; Lefebvre P; Pilon D; George DJ -
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.
N Engl J Med Volume: 392 Page(s): 45 - 55
01/02/2025 Authors: Apolo AB; Ballman KV; Sonpavde G; Berg S; Kim WY; Parikh R; Teo MY; Sweis RF; Geynisman DM; Grivas P -
Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors.
Volume: 17 Page(s): 17588359251316243
01/01/2025 Authors: Yildirim A; Wei M; Liu Y; Nazha B; Brown JT; Carthon BC; Choi Y; Suh L; Goswamy RV; McClintock GR -
The role of immunotherapy in targeting tumor microenvironment in genitourinary cancers.
Front Immunol Volume: 16 Page(s): 1506278
01/01/2025 Authors: Kalemoglu E; Jani Y; Canaslan K; Bilen MA -
Understanding and overcoming resistance to immunotherapy in genitourinary cancers.
Cancer Biol Ther Volume: 25 Page(s): 2342599
12/31/2024 Authors: Evans ST; Jani Y; Jansen CS; Yildirim A; Kalemoglu E; Bilen MA -
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial.
Nat Commun Volume: 15 Page(s): 10743
12/30/2024 Authors: Stein MN; Dumbrava EE; Teply BA; Gergis US; Guiterrez ME; Reshef R; Subudhi SK; Jacquemont CF; Senesac JH; Bayle JH -
Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers.
Commun Med (Lond) Volume: 4 Page(s): 256
12/02/2024 Authors: Barnett RM; Jang A; Lanka S; Fu P; Bucheit LA; Babiker H; Bryce A; Meyer HM; Choi Y; Moore C -
Differentiation fate of a stem-like CD4 T cell controls immunity to cancer.
Nature Volume: 636 Page(s): 224 - 232
12/01/2024 Authors: Cardenas MA; Prokhnevska N; Sobierajska E; Gregorova P; Medina CB; Valanparambil RM; Greenwald R; DelBalzo L; Bilen MA; Joshi SS -
Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146.
Eur Urol Volume: 86 Page(s): 470 - 473
11/01/2024 Authors: Lee C-H; Yogesh Shah A; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Girons Sarri R; Lee Cohn A; Asim Bilen M -
PD-L1 and nectin-4 expression and genomic characterization of bladder cancer with divergent differentiation.
Cancer Volume: 130 Page(s): 3658 - 3670
11/01/2024 Authors: Martini DJ; Case KB; Gratz D; Pellegrini K; Beagle E; Schneider T; Dababneh M; Nazha B; Brown JT; Joshi SS -
Author Correction: Differentiation fate of a stem-like CD4 T cell controls immunity to cancer.
Nature Volume: 635 Page(s): E9
11/01/2024 Authors: Cardenas MA; Prokhnevska N; Sobierajska E; Gregorova P; Medina CB; Valanparambil RM; Greenwald R; DelBalzo L; Bilen MA; Joshi SS -
Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy Approaches.
Oncologist Volume: 29 Page(s): 738 - 746
09/06/2024 Authors: Chukkalore D; MacDougall K; Master V; Bilen MA; Nazha B -
Transcriptome- and proteome-wide association studies identify genes associated with renal cell carcinoma.
Am J Hum Genet Volume: 111 Page(s): 1864 - 1876
09/05/2024 Authors: Dutta D; Guo X; Winter TD; Jahagirdar O; Renal Cancer Genetics Consortium; Ha E; Susztak K; Machiela MJ; Chanock SJ; Purdue MP -
Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09).
J Clin Oncol Volume: 42 Page(s): 2800 - 2811
08/10/2024 Authors: Tannir NM; Formiga MN; Penkov K; Kislov N; Vasiliev A; Gunnar Skare N; Hong W; Dai S; Tang L; Qureshi A -
Neoadjuvant cabozantinib restores CD8+ T cells in patients with locally advanced non-metastatic clear cell renal cell carcinoma: a phase 2 trial.
Res Sq
08/08/2024 Authors: Bilen MA; Vo BT; Liu Y; Greenwald R; Davarpanah AH; McGuire D; Shiradkar R; Li L; Nazha B; Brown JT -
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study.
Lancet Oncol Volume: 25 Page(s): 1038 - 1052
08/01/2024 Authors: Allaf ME; Kim S-E; Master V; McDermott DF; Harshman LC; Cole SM; Drake CG; Signoretti S; Akgul M; Baniak N -
DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes.
JCO Precis Oncol Volume: 8 Page(s): e2400014
08/01/2024 Authors: Graham LS; Henderson NC; Kellezi O; Hwang C; Barata PC; Bilen MA; Kilari D; Pierro M; Thapa B; Tripathi A -
Circulating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications.
Cancers (Basel) Volume: 16
06/20/2024 Authors: Gerke MB; Jansen CS; Bilen MA -
The impact of cancer metastases on COVID-19 outcomes: ACOVID-19 and Cancer Consortium registry-based retrospective cohort study.
Cancer Volume: 130 Page(s): 2191 - 2204
06/15/2024 Authors: Castellano CA; Sun T; Ravindranathan D; Hwang C; Balanchivadze N; Singh SRK; Griffiths EA; Puzanov I; Ruiz-Garcia E; Vilar-Compte D -
Linear Muscle Segmentation for Metastatic Renal Cell Carcinoma: Changes in Clinic-Friendly Estimation Predict Survival Following Cytoreductive Nephrectomy.
Clin Genitourin Cancer Volume: 22 Page(s): 102056
06/01/2024 Authors: Nicaise EH; Schmeusser BN; Ali A; Midenberg E; Palacios AR; Hartsoe B; Kearns E; Ambadi S; Patil DH; Joshi SS -
Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma.
J Clin Invest Volume: 134
05/30/2024 Authors: Gulati S; Barata PC; Elliott A; Bilen MA; Burgess EF; Choueiri TK; Darabi S; Dawson NA; Gartrell BA; Hammers HJ -
Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade.
Cancer Volume: 130 Page(s): 1642 - 1649
05/01/2024 Authors: Miller EJ; Rose TL; Maughan BL; Milowsky MI; Bilen MA; Carthon BC; Gao X; Rapisuwon S; Zhao Q; Yu M -
Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions.
Nat Genet Volume: 56 Page(s): 809 - 818
05/01/2024 Authors: Purdue MP; Dutta D; Machiela MJ; Gorman BR; Winter T; Okuhara D; Cleland S; Ferreiro-Iglesias A; Scheet P; Liu A -
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles.
J Clin Invest Volume: 134
04/23/2024 Authors: Barata P; Gulati S; Elliott A; Hammers HJ; Burgess E; Gartrell BA; Darabi S; Bilen MA; Basu A; Geynisman DM -
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res Volume: 30 Page(s): 1488 - 1500
04/15/2024 Authors: Dorff T; Horvath LG; Autio K; Bernard-Tessier A; Rettig MB; Machiels J-P; Bilen MA; Lolkema MP; Adra N; Rottey S -
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
J Immunother Cancer Volume: 12
04/11/2024 Authors: Atkins MB; Jegede OA; Haas NB; Mcdermott DF; Bilen MA; Stein M; Sosman J; Alter R; Plimack ER; Ornstein MC -
Established and emerging biomarkers of immunotherapy in renal cell carcinoma.
Immunotherapy Volume: 16 Page(s): 405 - 426
04/01/2024 Authors: Jani Y; Jansen CS; Gerke MB; Bilen MA -
Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations.
JCO Precis Oncol Volume: 8 Page(s): e2300567
04/01/2024 Authors: Park JJ; Chu A; Li J; Ali A; McKay RR; Hwang C; Labriola MK; Jang A; Kilari D; Mo G -
Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis.
J Immunother Cancer Volume: 12
03/26/2024 Authors: Patel JS; Woo Y; Draper A; Jansen CS; Carlisle JW; Innominato PF; Lvi FA; Dhabaan L; Master VA; Bilen MA -
Genetic Profiling of African American Patients With Prostatic Adenocarcinoma Metastatic to the Lymph Nodes: A Pilot Study.
Arch Pathol Lab Med Volume: 148 Page(s): 310 - 317
03/01/2024 Authors: Bidot S; Yin J; Zhou P; Zhang L; Deeb KK; Smith G; Hill CE; Xiu J; Bilen MA; Case KB -
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
Future Oncol Volume: 20 Page(s): 351 - 360
03/01/2024 Authors: Hoimes CJ; Flaig TW; Milowsky MI; Friedlander TW; Bilen MA; Gupta S; Srinivas S; Merchan JR; McKay RR; Petrylak DP -
2018 Leibovich prognostic model for renal cell carcinoma: Performance in a large population with special consideration of Black race.
Cancer Volume: 130 Page(s): 453 - 466
02/01/2024 Authors: Schmeusser BN; Patil DH; Nicaise EH; Armas-Phan M; Nabavizadeh R; Narayan VM; Joshi SS; Ogan K; Osunkoya AO; Bilen MA -
Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201.
Ann Oncol Volume: 35 Page(s): 200 - 210
02/01/2024 Authors: Necchi A; Pouessel D; Leibowitz R; Gupta S; Flchon A; Garca-Donas J; Bilen MA; Debruyne PR; Milowsky MI; Friedlander T -
Cytoreductive surgery, systemic treatment, genetic evaluation, and patient perspective in a young adult with metastatic renal cell carcinoma.
CA Cancer J Clin Volume: 74 Page(s): 323 - 338
01/01/2024 Authors: Nicaise EH; Yildirim A; Sheth S; Richter E; Daneshmand MA; Maithel SK; Ogan K; Bilen MA; Master VA -
The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers.
Biomark Insights Volume: 19 Page(s): 11772719241254179
01/01/2024 Authors: Seema Mustafa; Jansen CS; Jani Y; Evans S; Zhuang TZ; Brown J; Nazha B; Master V; Bilen MA -
Perioperative systemic treatments in renal cell carcinoma.
Front Oncol Volume: 14 Page(s): 1362172
01/01/2024 Authors: Goswamy R; Kalemoglu E; Master V; Bilen MA -
Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial.
BMJ Oncol Volume: 3 Page(s): e000181
01/01/2024 Authors: Tucker M; Chen Y-W; Voss MH; McGregor BA; Bilen MA; Grimm M-O; Nathan P; Kollmannsberger C; Tomita Y; Huang B -
Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race.
Clinicoecon Outcomes Res Volume: 16 Page(s): 657 - 674
01/01/2024 Authors: Bilen MA; Khilfeh I; Rossi C; Muser E; Morrison L; Hilts A; Diaz L; Lefebvre P; Pilon D; George DJ -
Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers.
Cancer Volume: 129 Page(s): 3884 - 3893
12/15/2023 Authors: Nazha B; Zhuang T; Wu S; Brown JT; Magee D; Carthon BC; Kucuk O; Nabhan C; Barata PC; Heath EI -
Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors.
Oncologist Volume: 28 Page(s): 1072 - 1078
12/11/2023 Authors: Sanda GE; Shabto JM; Goyal S; Liu Y; Martini DJ; Nazha B; Brown JT; Yantorni LB; Anne Russler G; Caulfield S -
Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast.
Oncologist Volume: 28 Page(s): 1055 - 1063
12/11/2023 Authors: Lalonde CS; Switchenko JM; Behera M; Bilen MA; Owonikoko TK; Kaufman JL; Nooka AK; Lewis CM; Hitron E; Collins H -
Creatinine to Cystatin-C Ratio in Renal Cell Carcinoma: A Clinically Pragmatic Prognostic Factor and Sarcopenia Biomarker.
Oncologist Volume: 28 Page(s): e1219 - e1229
12/11/2023 Authors: Schmeusser BN; Biermann H; Nicaise EH; Ali AA; Patil DH; Midenberg E; Helman T; Armas-Phan M; Nabavizadeh R; Joshi SS -
The Genomic Landscape of Urothelial Carcinoma with High and Low ERBB2 Expression.
Cancers (Basel) Volume: 15
12/06/2023 Authors: Hadadi A; Krause HB; Elliott A; Brown JT; Nazha B; Harik LR; Carthon BC; Miron B; Nabhan C; Barata PC -
Prostate Cancer Skeletal Metastasis: A Spontaneous Evolution from Osteolytic to Osteoblastic Morphology without Treatment.
World J Nucl Med Volume: 22 Page(s): 316 - 320
12/01/2023 Authors: Lawal IO; Bilen MA; Halkar RK; Jani AB; Schuster DM -
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study.
Elife Volume: 12
10/17/2023 Authors: Nagaraj G; Vinayak S; Khaki AR; Sun T; Kuderer NM; Aboulafia DM; Acoba JD; Awosika J; Bakouny Z; Balmaceda NB -
Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study).
Oncologist Volume: 28 Page(s): 790 - 798
09/07/2023 Authors: Bilen MA; Robinson SB; Schroeder A; Peng J; Kim R; Liu FX; Bhanegaonkar A -
Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.
JAMA Netw Open Volume: 6 Page(s): e2334208
09/05/2023 Authors: Hwang C; Henderson NC; Chu S-C; Holland B; Cackowski FC; Pilling A; Jang A; Rothstein S; Labriola M; Park JJ -
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
J Clin Oncol Volume: 41 Page(s): 4107 - 4117
09/01/2023 Authors: O'Donnell PH; Milowsky MI; Petrylak DP; Hoimes CJ; Flaig TW; Mar N; Moon HH; Friedlander TW; McKay RR; Bilen MA -
A Phase 1/2, open label dose-escalation and expansion trial of NKT2152, an orally administered HIF2a inhibitor, to investigate safety, PK, PD and clinical activity in patients with advanced ccRCC
Volume: 28 Page(s): S12 - S12
09/01/2023 Authors: Jonasch E; Hauke R; Falchook G; Logan T; Gordon M; Hall E; Schuch B; Bilen MA; Naqash A; Zakaharia Y -
Identifying the Needs of Health Care Providers in Advanced First-Line Renal Cell Carcinoma: A Mixed-Methods Research.
Clin Genitourin Cancer Volume: 21 Page(s): e299 - e308
08/01/2023 Authors: Lazure P; Campbell MT; Augustyniak M; Jaimes EA; Bilen MA; Lemke EA; Cohen EP; Jacobs G -
Low Skeletal Muscle as a Risk Factor for Worse Survival in Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus.
Clin Genitourin Cancer Volume: 21 Page(s): 475 - 482.e4
08/01/2023 Authors: Schmeusser BN; Midenberg E; Palacios AR; Ali AA; Patil DH; Higgins M; Nabavizadeh R; Croll B; Williams M; Sheehy J -
COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease.
Transl Oncol Volume: 34 Page(s): 101709
08/01/2023 Authors: Moey MYY; Hennessy C; French B; Warner JL; Tucker MD; Hausrath DJ; Shah DP; DeCara JM; Bakouny Z; Labaki C -
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Lancet Oncol Volume: 24 Page(s): 925 - 935
08/01/2023 Authors: Pant S; Schuler M; Iyer G; Witt O; Doi T; Qin S; Tabernero J; Reardon DA; Massard C; Minchom A -
Genetic Profiling of African American Patients With Prostatic Adenocarcinoma Metastatic to the Lymph Nodes: A Pilot Study
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
06/19/2023 Authors: Bidot S; Yin J; Zhou P; Zhang L; Deeb K; Smith GH; Hill C; Xiu J; Bilen M; Case K -
HEALTHCARE RESOURCE UTILIZATION (HCRU) AND COSTS IN PATIENTS WITH METASTATIC UROTHELIAL CANCER (MUC) WHO RECEIVED FIRST-LINE (1L) TREATMENT: RESULTS FROM IMPACT UC II
Volume: 26 Page(s): S131 - S131
06/01/2023 Authors: Bilen MA; Diessner B; White J; Kirker M; Liu F; Nguyen A; Gharibian N; Devgan G; Katzenstein H; Bhanegaonkar A -
Combined Programmed Death-Ligand 1 and MET Inhibition: Has Papillary Renal Cell Carcinoma MET Its Match?
J Clin Oncol Volume: 41 Page(s): 2467 - 2470
05/10/2023 Authors: Brown JT; Nazha B; Bilen MA -
Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas.
Oncologist Volume: 28 Page(s): 433 - 439
05/08/2023 Authors: Alhalabi O; Thouvenin J; Ngrier S; Vano Y-A; Campedel L; Hasanov E; Bakouny Z; Hahn AW; Bilen MA; Msaouel P -
Clinicopathologic analysis of patients undergoing repeat transurethral resection of bladder tumour following an initial diagnosis of urothelial carcinoma with lamina propria invasion and variant/divergent histology.
Volume: 76 Page(s): 256 - 260
04/01/2023 Authors: Mullane P; Joshi S; Bilen M; Osunkoya AO -
IMPLICATIONS OF RACE FREE RENAL FUNCTION EQUATIONS ON BLACK PATIENTS WITH RENAL CELL CARCINOMA
Volume: 209 Page(s): E133 - E134
04/01/2023 Authors: Schmeusser BN; Palacios AR; Midenberg E; Nabavizadeh R; Ali A; Patil DH; Harvey RD; Bryksin J; Connor MJ; Ogan K -
Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma.
BMC Cancer Volume: 23 Page(s): 265
03/23/2023 Authors: Johnson DB; Atkins MB; Hennessy C; Wise-Draper T; Heilman H; Awosika J; Bakouny Z; Labaki C; Saliby RM; Hwang C -
Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Oncologist Volume: 28 Page(s): 239 - 245
03/17/2023 Authors: Zhuang TZ; Ravindranathan D; Liu Y; Martini DJ; Brown JT; Nazha B; Russler G; Yantorni LB; Caulfield S; Carthon BC -
Race-free renal function estimation equations and potential impact on Black patients: Implications for cancer clinical trial enrollment.
Cancer Volume: 129 Page(s): 920 - 924
03/15/2023 Authors: Schmeusser BN; Palacios AR; Midenberg ER; Nabavizadeh R; Patil DH; Harvey RD; Bryksin J; Connor MJ; Ogan K; Bilen MA -
Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.
medRxiv
03/10/2023 Authors: Nagaraj G; Vinayak S; Khaki AR; Sun T; Kuderer NM; Aboulafia DM; Acoba JD; Awosika J; Bakouny Z; Balmaceda NB -
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-nave patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).
J Immunother Cancer Volume: 11
03/01/2023 Authors: Atkins MB; Jegede OA; Haas NB; McDermott DF; Bilen MA; Stein M; Sosman JA; Alter R; Plimack ER; Ornstein MC -
Association of inflammation and depression in renal cell carcinoma.
Volume: 41
02/20/2023 Authors: Schmeusser B; Ali A; Patil DH; Midenberg E; Petrinec B; Bilen MA; Ogan K; Master VA -
Effect of race-free estimated glomerular filtration rate equations (eGFR) on oncology clinical trial eligibility for Black patients.
Volume: 41
02/20/2023 Authors: Schmeusser B; Palacios AR; Midenberg E; Nabavizadeh R; Patil DH; Harvey RD; Bryksin J; Connor MJ; Ogan K; Bilen MA -
Time-to-next treatment (TTNT) and overall survival (OS) among homologous recombination repair (HRR) positive and HRR negative patients with metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapy.
Volume: 41
02/20/2023 Authors: Bilen MA; Khilfeh I; Rossi C; Muser E; Morrison L; Hilts A; Waters D; Lefebvre P; Pilon D; George DJ -
Adjuvant immunotherapy in renal cell carcinoma: A living systematic review and network meta-analysis (NMA).
Volume: 41
02/20/2023 Authors: Sipra QUAR; Bin Riaz I; Naqvi SAA; He H; Siddiqi R; Islam M; Asghar N; Ikram W; Xu WV; Singh P -
Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma.
Clin Genitourin Cancer Volume: 21 Page(s): 55 - 62
02/01/2023 Authors: Shayeb AM; McManus HD; Urman D; Jani C; Zhang T; Dizman N; Meza L; Sivakumar A; Gan CL; Barata P -
Neoadjuvant Nivolumab and Ipilimumab for Nonmetastatic Renal Cell Carcinoma with Tumor Thrombus.
J Immunother Precis Oncol Volume: 6 Page(s): 50 - 55
02/01/2023 Authors: Master VA; Schmeusser BN; Osunkoya AO; Palacios AR; Midenberg E; Yantorni L; Ogan K; Bilen MA -
Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.
JCO Precis Oncol Volume: 7 Page(s): e2200505
02/01/2023 Authors: Yang ES; Halabi S; Rothe M; Garrett-Mayer E; Mangat PK; Pisick E; Dib E; Burgess EF; Zakem M; Rohatgi N -
CD8+ Tcell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor.
Immunity Volume: 56 Page(s): 107 - 124.e5
01/10/2023 Authors: Prokhnevska N; Cardenas MA; Valanparambil RM; Sobierajska E; Barwick BG; Jansen C; Reyes Moon A; Gregorova P; delBalzo L; Greenwald R -
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.
J Clin Oncol Volume: 41 Page(s): 22 - 31
01/01/2023 Authors: Hoimes CJ; Flaig TW; Milowsky MI; Friedlander TW; Bilen MA; Gupta S; Srinivas S; Merchan JR; McKay RR; Petrylak DP -
Prognostic Value of Sarcopenia and Albumin in the Surgical Management of Localized Renal Cell Carcinoma.
Urol Oncol Volume: 41 Page(s): 50.e19 - 50.e26
01/01/2023 Authors: Midenberg E; Higgins MI; Schmeusser BN; Patil DH; Zaldumbide J; Martini DJ; Steele S; Williams M; Nabavizadeh R; Psutka SP -
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.
JAMA Oncol Volume: 9 Page(s): 128 - 134
01/01/2023 Authors: Bakouny Z; Labaki C; Grover P; Awosika J; Gulati S; Hsu C-Y; Alimohamed SI; Bashir B; Berg S; Bilen MA -
Challenges and opportunities in the management of non-urothelial bladder cancers.
Cancer Treat Res Commun Volume: 34 Page(s): 100663
01/01/2023 Authors: Brown JT; Narayan VM; Joshi SS; Harik L; Jani AB; Bilen MA -
Editorial: Case reports in renal cell carcinoma.
Front Oncol Volume: 13 Page(s): 1165013
01/01/2023 Authors: Zhuang TZ; Mustafa SM; Beckermann KE; Bilen MA -
Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma.
Front Oncol Volume: 13 Page(s): 1271255
01/01/2023 Authors: Jansen CS; Choi Y; Evans ST; Greenwald R; Behnke JA; Hartman C; Kissick H; Harik LR; Bilen MA -
Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas.
Oncologist Volume: 27 Page(s): 1041 - 1047
12/09/2022 Authors: Thouvenin J; Alhalabi O; Carlo M; Carril-Ajuria L; Hirsch L; Martinez-Chanza N; Ngrier S; Campedel L; Martini D; Borchiellini D -
Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [68Ga]Ga DOTATATE PET-CT.
Cancers (Basel) Volume: 14
12/08/2022 Authors: Bilen MA; Akintayo A; Liu Y; Abiodun-Ojo O; Kucuk O; Carthon BC; Schuster DM; Parent EE -
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.
Clin Genitourin Cancer Volume: 20 Page(s): 558 - 567
12/01/2022 Authors: Talukder R; Makrakis D; Lin GI; Diamantopoulos LN; Dawsey S; Gupta S; Carril-Ajuria L; Castellano D; de Kouchkovsky I; Jindal T -
Data regarding covariates significantly associated with sarcopenia and varying albumin statuses in patients with renal cell carcinoma.
Data Brief Volume: 45 Page(s): 108724
12/01/2022 Authors: Schmeusser BN; Patil DH; Midenberg E; Higgins MI; Zaldumbide J; Martini DJ; Steele S; Williams M; Nabavizadeh R; Psutka SP -
Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry.
Eur J Cancer Volume: 177 Page(s): 197 - 205
12/01/2022 Authors: Nowatzke J; Guedeney P; Palaskas N; Lehmann L; Ederhy S; Zhu H; Cautela J; Francis S; Courand P-Y; Deswal A -
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.
BJU Int Volume: 130 Page(s): 592 - 603
11/01/2022 Authors: Makrakis D; Talukder R; Diamantopoulos LN; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Koshkin VS; Park JJ; Alva A; Bilen MA -
Risk Stratification of Prostatic Adenocarcinoma Metastatic to the Lymph Nodes.
Arch Pathol Lab Med Volume: 146 Page(s): 1345 - 1352
11/01/2022 Authors: Bidot S; Monsrud A; Kline M; Speak A; Martini D; Bilen MA; Switchenko JM; Zhang Y; Gerges AG; Farhat GN -
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
Eur Urol Volume: 82 Page(s): 365 - 373
10/01/2022 Authors: Siefker-Radtke AO; Cho DC; Diab A; Sznol M; Bilen MA; Balar AV; Grignani G; Puente E; Tang L; Chien D -
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
Clin Genitourin Cancer Volume: 20 Page(s): e440 - e452
10/01/2022 Authors: Makrakis D; Talukder R; Lin GI; Diamantopoulos LN; Dawsey S; Gupta S; Carril-Ajuria L; Castellano D; de Kouchkovsky I; Koshkin VS -
Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race.
Oncologist Volume: 27 Page(s): e815 - e818
10/01/2022 Authors: Zimmerman R; Bilen MA; Heath EI; Nandagopal L; Swami U; Kessel A; Jaeger E; Wesolowski S; Hernanadez EJ; Chipman J -
Impact of first-line (1L) therapy on outcomes of adult patients (pts) with metastatic MiT family translocation renal cell carcinomas (TRCC) treated in the contemporary immune checkpoint therapy (ICT) era
Volume: 33 Page(s): S1213 - S1214
09/13/2022 Authors: Thouvenin J; Alhalabi O; Carlo M; Ajuria LC; Bakouny Z; Chanza NM; Negrier S; Campedel L; Bilen MA; Borchiellini D -
Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study.
Cancers (Basel) Volume: 14
09/05/2022 Authors: Wagner MJ; Hennessy C; Beeghly A; French B; Shah DP; Croessmann S; Vilar-Compte D; Ruiz-Garcia E; Ingham M; Schwartz GK -
PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer.
Prostate Cancer Prostatic Dis Volume: 25 Page(s): 388 - 396
09/01/2022 Authors: Koshkin VS; Patel VG; Ali A; Bilen MA; Ravindranathan D; Park JJ; Kellezi O; Cieslik M; Shaya J; Cabal A -
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).
J Clin Oncol Volume: 40 Page(s): 2913 - 2923
09/01/2022 Authors: Atkins MB; Jegede OA; Haas NB; McDermott DF; Bilen MA; Stein M; Sosman JA; Alter R; Plimack ER; Ornstein M -
An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma.
CA Cancer J Clin Volume: 72 Page(s): 454 - 489
09/01/2022 Authors: Hasanov E; Yeboa DN; Tucker MD; Swanson TA; Beckham TH; Rini B; Ene CI; Hasanov M; Derks S; Smits M -
Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling (CGP) of cell-free DNA (cfDNA)
Volume: 33 Page(s): S1175 - S1175
09/01/2022 Authors: Reisinger R; Swami U; Hernandez EJ; Sayegh N; Wesolowski S; Kiedrowski L; Barata PMC; Nussenzveig R; Lemmon G; Bilen MA -
Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience.
J Immunother Precis Oncol Volume: 5 Page(s): 52 - 57
08/01/2022 Authors: Martini DJ; Olsen TA; Goyal S; Liu Y; Evans ST; Hitron EE; Russler GA; Yantorni L; Caulfield S; Brown JT -
Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis.
Crit Rev Oncol Hematol Volume: 175 Page(s): 103706
07/01/2022 Authors: Riaz IB; Sipra QUAR; Naqvi SAA; He H; Siddiqi R; Islam M; Asghar N; Ikram W; Xu W; Liu H -
ESTIMATED COSTS FOR ALL-CAUSE GRADE 3/4 ADVERSE EVENTS AMONG FIRST-LINE TYROSINE KINASE INHIBITOR PLUS IMMUNO-ONCOLOGY-BASED COMBINATION THERAPIES FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA FROM THE UNITED STATES PERSPECTIVE
Volume: 25 Page(s): S361 - S361
07/01/2022 Authors: Wallace JF; Adair N; Perez JR; Hall T; Bilen MA; Sussman M -
Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood.
J Immunother Cancer Volume: 10
07/01/2022 Authors: Carlisle JW; Jansen CS; Cardenas MA; Sobierajska E; Reyes AM; Greenwald R; Del Balzo L; Prokhnevska N; Kucuk O; Carthon BC -
High throughput, label-free isolation of circulating tumor cell clusters in meshed microwells.
Nat Commun Volume: 13 Page(s): 3385
06/13/2022 Authors: Boya M; Ozkaya-Ahmadov T; Swain BE; Chu C-H; Asmare N; Civelekoglu O; Liu R; Lee D; Tobia S; Biliya S -
Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials.
Cancers (Basel) Volume: 14
06/10/2022 Authors: Zhuang TZ; Case K; Olsen TA; Brown JT; Carthon BC; Kucuk O; Goldman J; Harris W; Bilen MA; Nazha B -
Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma.
Oncologist Volume: 27 Page(s): 462 - 468
06/08/2022 Authors: Nazha B; Zhuang TZ; Dada HI; Drusbosky LM; Brown JT; Ravindranathan D; Carthon BC; Kucuk O; Goldman J; Master VA -
Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Cancer Volume: 128 Page(s): 2073 - 2084
06/01/2022 Authors: Khan AI; Psutka SP; Patil DH; Hong G; Williams MA; Bilen MA; Sekhar A; Kissick HT; Narayan VM; Joshi SS -
Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer.
Urol Oncol Volume: 40 Page(s): 271.e9 - 271.e18
06/01/2022 Authors: Hadadi A; Smith KE; Wan L; Brown JR; Russler G; Yantorni L; Caulfield S; Lafollette J; Moore M; Kucuk O -
Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19.
Blood Cancer Discov Volume: 3 Page(s): 181 - 193
05/05/2022 Authors: Rubinstein SM; Bhutani D; Lynch RC; Hsu C-Y; Shyr Y; Advani S; Mesa RA; Mishra S; Mundt DP; Shah DP -
Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.
Clin Genitourin Cancer Volume: 20 Page(s): 165 - 175
04/01/2022 Authors: Talukder R; Makrakis D; Diamantopoulos LN; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Koshkin VS; Park JJ; Alva A; Bilen MA -
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.
J Immunother Cancer Volume: 10
04/01/2022 Authors: Tannir NM; Cho DC; Diab A; Sznol M; Bilen MA; Balar AV; Grignani G; Puente E; Tang L; Chien D -
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Cancer Volume: 128 Page(s): 1194 - 1205
03/15/2022 Authors: Koshkin VS; Henderson N; James M; Natesan D; Freeman D; Nizam A; Su CT; Khaki AR; Osterman CK; Glover MJ -
Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer.
Oncologist Volume: 27 Page(s): 220 - 227
03/11/2022 Authors: Freeman MN; Jang A; Zhu J; Sanati F; Nandagopal L; Ravindranathan D; Desai A; Phone A; Nussenzveig R; Jaeger E -
Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer.
JAMA Netw Open Volume: 5 Page(s): e224304
03/01/2022 Authors: Fu J; Reid SA; French B; Hennessy C; Hwang C; Gatson NT; Duma N; Mishra S; Nguyen R; Hawley JE -
Genetic Profiling of African American Patients with Prostatic Adenocarcinoma Metastatic to the Lymph Node
Volume: 102 Page(s): 571 - 572
03/01/2022 Authors: Bidot S; Yin J; Zhang L; Deeb K; Hill C; Xiu J; Bilen M; Case K; Harik L -
Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial.
Clin Cancer Res Volume: 28 Page(s): 738 - 747
02/15/2022 Authors: Bilen MA; Rini BI; Voss MH; Larkin J; Haanen JBAG; Albiges L; Pagliaro LC; Voog EG; Lam ET; Kislov N -
Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients.
Clin Genitourin Cancer Volume: 20 Page(s): 53 - 59
02/01/2022 Authors: Martini DJ; Evans ST; Liu Y; Shabto JM; Uner OE; Olsen TA; Brown JT; Russler GA; Yantorni L; Caulfield S -
Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.
JAMA Netw Open Volume: 5 Page(s): e2142046
01/04/2022 Authors: Hawley JE; Sun T; Chism DD; Duma N; Fu JC; Gatson NTN; Mishra S; Nguyen RH; Reid SA; Serrano OK -
Correlates of financial toxicity in adult cancer patients and their informal caregivers.
Support Care Cancer Volume: 30 Page(s): 217 - 225
01/01/2022 Authors: Sadigh G; Switchenko J; Weaver KE; Elchoufi D; Meisel J; Bilen MA; Lawson D; Cella D; El-Rayes B; Carlos R -
Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy.
Front Endocrinol (Lausanne) Volume: 13 Page(s): 779915
01/01/2022 Authors: Olsen TA; Zhuang TZ; Caulfield S; Martini DJ; Brown JT; Carthon BC; Kucuk O; Harris W; Bilen MA; Nazha B -
Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA.
Front Oncol Volume: 12 Page(s): 966534
01/01/2022 Authors: Swami U; Zimmerman RM; Nussenzveig RH; Hernandez EJ; Jo Y; Sayegh N; Wesolowski S; Kiedrowski LA; Barata PC; Lemmon GH -
Clinic friendly estimation of muscle composition: Preoperative linear segmentation shows overall survival correlated with muscle mass in patients with nonmetastatic renal cell carcinoma.
Front Oncol Volume: 12 Page(s): 1068357
01/01/2022 Authors: Schmeusser BN; Midenberg E; Palacios AR; Vettikattu N; Patil DH; Medline A; Higgins M; Armas-Phan M; Nabavizadeh R; Joshi SS -
Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah's witness: A case report.
Front Oncol Volume: 12 Page(s): 949400
01/01/2022 Authors: Zhuang TZ; Harik L; Force S; Hadadi A; Bilen MA; Brown JT; Carthon BC; Goldman J; Kucuk O; Master VA -
Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors.
Oncologist Volume: 26 Page(s): 1017 - 1025
12/01/2021 Authors: Martini DJ; Shabto JM; Goyal S; Liu Y; Olsen TA; Evans ST; Magod BL; Ravindranathan D; Brown JT; Yantorni L -
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma.
JAMA Oncol Volume: 7 Page(s): 1815 - 1823
12/01/2021 Authors: Hirsch L; Martinez Chanza N; Farah S; Xie W; Flippot R; Braun DA; Rathi N; Thouvenin J; Collier KA; Seront E -
Understanding Immunotherapy Terminology: An Analysis of Provider-Patient Conversations.
Immunomedicine Volume: 1
12/01/2021 Authors: Blee S; Rosenberg B; Switchenko JM; Hianik R; Thomson MC; Dixon M; Bilen MA; Pentz RD -
Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options.
Oncologist Volume: 26 Page(s): 956 - 964
11/01/2021 Authors: Smith KER; Brown JT; Wan L; Liu Y; Russler G; Yantorni L; Caulfield S; Lafollette J; Moore M; Kucuk O -
Retrospective Study of Bleeding Risk with Concomitant Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor and Anticoagulation.
Oncologist Volume: 26 Page(s): e2061 - e2069
11/01/2021 Authors: Sivakumar A; Caulfield SE; Zhang C; Goyal S; Bilen MA; Beardslee TJ -
Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.
JAMA Netw Open Volume: 4 Page(s): e2134330
11/01/2021 Authors: Schmidt AL; Tucker MD; Bakouny Z; Labaki C; Hsu C-Y; Shyr Y; Armstrong AJ; Beer TM; Bijjula RR; Bilen MA -
Sarcopenia and Modified Glasgow Prognostic Score Predict Outcomes Following Surgical Resection of Renal Cell Carcinoma with Inferior Vena Cava Thrombus
Volume: 233 Page(s): E232 - E232
11/01/2021 Authors: Higgins M; Manalo T; Patil DH; Nabavizadeh R; Martini D; Bilen MA; Master VA -
DISSECTING INTRATUMORAL IMMUNE ORGANIZATION: DEFINING THE COMPARATIVE CELLULAR COMPOSITION OF TERTIARY LYMPHOID STRUCTURES T-CELL SUPPORTIVE ANTIGEN PRESENTING NICHES IN RENAL TUMORS
Volume: 9 Page(s): A975 - A975
11/01/2021 Authors: Jansen C; Sobierajska E; Greenwald R; Carlisle J; Mullane P; Prokhnevska N; Cardenas M; Bilen M; Osunkoya A; Master V -
Negative enrichment of circulating tumor cells from unmanipulated whole blood with a 3D printed device.
Sci Rep Volume: 11 Page(s): 20583
10/18/2021 Authors: Chu C-H; Liu R; Ozkaya-Ahmadov T; Swain BE; Boya M; El-Rayes B; Akce M; Bilen MA; Kucuk O; Sarioglu AF -
Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
Cancers (Basel) Volume: 13
10/10/2021 Authors: Jang A; Adler DM; Rauterkus GP; Bilen MA; Barata PC -
Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors.
Clin Genitourin Cancer Volume: 19 Page(s): 425 - 433
10/01/2021 Authors: Pond GR; Agarwal A; Ornstein M; Garcia J; Gupta R; Grivas P; Drakaki A; Lee J-L; Kanesvaran R; Lorenzo GD -
Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Oncologist Volume: 26 Page(s): e1742 - e1750
10/01/2021 Authors: Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA -
Gene expression profiling (GEP) signatures associated with markers of sensitivity to immune and angiogenic therapy in clear-cell renal cell carcinoma (ccRCC) with sarcomatoid/rhabdoid features
Volume: 32 Page(s): S705 - S705
09/21/2021 Authors: Barata PMC; Gulati S; Elliott A; Rao A; Burgess EF; Mckay R; Hammers HJ; Gartrell B; Darabi S; Bilen MA -
Evaluation of concordance between PD-L1 immunohistochemistry 28-8 and 22C3 pharmDx assays in metastatic urothelial carcinoma (mUC) in PIVOT-10
Volume: 32 Page(s): S392 - S393
09/21/2021 Authors: Siefker-Radtke AO; Hoch U; Loriot Y; Balar AV; Bilen MA; Tannir NM; Cho DC; Choudhury A; Chien D; Yu D -
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.
BJU Int Volume: 128 Page(s): 196 - 205
08/01/2021 Authors: Esagian SM; Khaki AR; Diamantopoulos LN; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Park JJ; Alva A; Bilen MA; Stewart TF -
Small-Cell Carcinoma of the Prostate: Report of Outcomes of Localized Disease Using the National Cancer Database.
Clin Genitourin Cancer Volume: 19 Page(s): e193 - e199
08/01/2021 Authors: Xu KM; Liu Y; Gillespie TW; Osunkoya AO; Carthon B; Bilen MA; Filson CP; Ogan K; Patel PR; Shelton JW -
Erratum to 'Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial': [ESMO Open Volume 6, Issue 3, June 2021, 100101].
ESMO Open Volume: 6 Page(s): 100177
08/01/2021 Authors: Choueiri TK; Larkin J; Pal S; Motzer RJ; Rini BI; Venugopal B; Alekseev B; Miyake H; Gravis G; Bilen MA -
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lancet Oncol Volume: 22 Page(s): 946 - 958
07/01/2021 Authors: Lee C-H; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R -
Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
J Immunother Cancer Volume: 9
07/01/2021 Authors: Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS -
Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma.
Cancer Volume: 127 Page(s): 1974 - 1983
06/15/2021 Authors: Higgins MI; Martini DJ; Patil DH; Nabavizadeh R; Steele S; Williams M; Joshi SS; Narayan VM; Sekhar A; Psutka SP -
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.
Eur Urol Oncol Volume: 4 Page(s): 464 - 472
06/01/2021 Authors: Khaki AR; Li A; Diamantopoulos LN; Miller NJ; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Koshkin V; Park J; Alva A -
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.
Ann Oncol Volume: 32 Page(s): 787 - 800
06/01/2021 Authors: Grivas P; Khaki AR; Wise-Draper TM; French B; Hennessy C; Hsu C-Y; Shyr Y; Li X; Choueiri TK; Painter CA -
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial.
ESMO Open Volume: 6 Page(s): 100101
06/01/2021 Authors: Choueiri TK; Larkin J; Pal S; Motzer RJ; Rini BI; Venugopal B; Alekseev B; Miyake H; Gravis G; Bilen MA -
TREATMENT PATTERN AND HEALTHCARE RESOURCE UTILIZATION (HRU) IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA (MUC) AMONG MEDICARE FEE-FOR-SERVICE (FFS) BENEFICIARIES: RESULTS FROM IMPACT UC
Volume: 24 Page(s): S65 - S65
06/01/2021 Authors: Bilen MA; Xi A; Schroeder A; Kim R; Liu F; Wong A; Peng J; Jones B; Robinson SB; Bhanegaonkar A -
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.
Lancet Volume: 397 Page(s): 1895 - 1904
05/22/2021 Authors: Jani AB; Schreibmann E; Goyal S; Halkar R; Hershatter B; Rossi PJ; Shelton JW; Patel PR; Xu KM; Goodman M -
Poorly Differentiated Neuroendocrine Tumor With 18F-Fluciclovine Uptake in a Patient With Metastatic Castrate-Resistant Prostate Cancer.
Clin Nucl Med Volume: 46 Page(s): e282 - e285
05/01/2021 Authors: Abiodun-Ojo OA; Akintayo AA; Harik LR; Bilen M; Halkar RK -
Circulating interleukin 6, androgen deprivation therapy, and fatigue in prostate cancer: Is inflammation the link?
Cancer Volume: 127 Page(s): 1371 - 1373
05/01/2021 Authors: Nazha B; Bilen MA -
Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
Oncologist Volume: 26 Page(s): 397 - 405
05/01/2021 Authors: Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni LB; Joshi SS -
Inflammatory Markers in Cancer Immunotherapy.
Biology (Basel) Volume: 10
04/13/2021 Authors: Ravindranathan D; Master VA; Bilen MA -
Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos.
J Vis Exp
03/21/2021 Authors: Steele S; Lin F; Le T-L; Medline A; Higgins M; Sandberg A; Evans S; Hong G; Williams MA; Bilen MA -
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.
Cancer Volume: 127 Page(s): 840 - 849
03/15/2021 Authors: McGregor BA; Campbell MT; Xie W; Farah S; Bilen MA; Schmidt AL; Sonpavde GP; Kilbridge KL; Choudhury AD; Mortazavi A -
Clinicopathologic Implications of Unifocal vs Multifocal Invasive Urothelial Carcinoma of the Bladder with Lamina Propria Invasion
Volume: 34 Page(s): 589 - 589
03/01/2021 Authors: Mullane P; Joshi S; Bilen M; Osunkoya AO -
Clinicopathologic Implications of Unifocal vs Multifocal Invasive Urothelial Carcinoma of the Bladder with Lamina Propria Invasion
Volume: 101 Page(s): 589 - 589
03/01/2021 Authors: Mullane P; Joshi S; Bilen M; Osunkoya AO -
Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report.
J Med Case Rep Volume: 15 Page(s): 72
02/19/2021 Authors: Olsen TA; Martini DJ; Evans ST; Goldman JM; Bilen MA -
Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody.
Am J Clin Oncol Volume: 44 Page(s): 74 - 81
02/01/2021 Authors: Akce M; Liu Y; Zakka K; Martini DJ; Draper A; Alese OB; Shaib WL; Wu C; Wedd JP; Sellers MT -
Successful Recruitment of Black Men to Prostate Cancer Clinical Trials-A Lesson in Achievement.
JAMA Netw Open Volume: 4 Page(s): e2034652
01/04/2021 Authors: Hahn AW; Bilen MA; Agarwal N -
Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib.
Volume: 28 Page(s): 100393
01/01/2021 Authors: Martini DJ; Kline MR; Liu Y; Shabto JM; Carthon BC; Russler GA; Yantorni L; Hitron EE; Caulfield S; Goldman JM -
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer.
Future Oncol Volume: 17 Page(s): 137 - 149
01/01/2021 Authors: Huddart RA; Siefker-Radtke AO; Balar AV; Bilen MA; Powles T; Bamias A; Castellano D; Khalil MF; Van Der Heijden MS; Koshkin VS -
Bladder preserving chemoradiotherapy compared to surgery for variants of urothelial carcinoma and other tumors types involving the bladder: An analysis of the National Cancer Database.
Clin Transl Radiat Oncol Volume: 26 Page(s): 30 - 34
01/01/2021 Authors: Janopaul-Naylor JR; Zhong J; Liu Y; Zhang C; Osunkoya AO; Joshi SS; Bilen MA; Carthon B; Kucuk O; Hartsell LM -
Detection of Microsatellite Instability via Circulating Tumor DNA and Response to Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: A Case Series.
Case Rep Oncol Volume: 14 Page(s): 190 - 196
01/01/2021 Authors: Ravindranathan D; Russler GA; Yantorni L; Drusbosky LM; Bilen MA -
Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade.
Front Oncol Volume: 11 Page(s): 701345
01/01/2021 Authors: Olsen TA; Martini DJ; Goyal S; Liu Y; Evans ST; Magod B; Brown JT; Yantorni L; Russler GA; Caulfield S -
Exploratory study of 18F-fluciclovine pet/ct for response assessment to docetaxel in patients with metastatic castration-resistant prostate cancer.
Am J Nucl Med Mol Imaging Volume: 11 Page(s): 218 - 229
01/01/2021 Authors: Akintayo AA; Bilen MA; Abiodun-Ojo OA; Kucuk O; Carthon B; Chen Z; Jani AB; Parent EE; Schuster DM -
Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors.
Front Oncol Volume: 11 Page(s): 707050
01/01/2021 Authors: Martini DJ; Olsen TA; Goyal S; Liu Y; Evans ST; Magod B; Brown JT; Yantorni L; Russler GA; Caulfield S -
Landscape of Immunotherapy in Genitourinary Malignancies.
Adv Exp Med Biol Volume: 1342 Page(s): 143 - 192
01/01/2021 Authors: Ravindranathan D; Alhalabi O; Rafei H; Shah AY; Bilen MA -
Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma.
Front Oncol Volume: 11 Page(s): 793808
01/01/2021 Authors: Martini DJ; Jansen CS; Harik LR; Evans ST; Olsen TA; Master VA; Kissick HT; Bilen MA -
A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance.
Cancer Cell Volume: 38 Page(s): 761 - 766
12/14/2020 Authors: COVID-19 and Cancer Consortium. Electronic address: jeremy.warner@vumc.org; COVID-19 and Cancer Consortium -
Initial Report of a Randomized Trial Comparing Conventional- vs Conventional plus Fluciclovine (18F) PET/CT Imaging-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer.
Volume: 108 Page(s): 1397
12/01/2020 Authors: Jani A; Schreibmann E; Goyal S; Raghuveer H; Hershatter B; Rossi PJ; Shelton JW; Patel PR; Xu KM; Goodman M -
First-line (1L) enfortumab vedotin plus pembrolizumab demonstrates durable antitumour activity in cisplatin-ineligible patients with locally advanced/metastatic urothelial carcinoma (la/mUC)
Page(s): 26S - 27S
11/18/2020 Authors: Rosenberg JE; Flaig TW; Friedlander TW; Milowsky MI; Srinivas S; Petrylak DP; Merchan JR; Bilen MA; Carret A-S; Yuan N -
Quantification of body composition in renal cell carcinoma patients: Comparing computed tomography and magnetic resonance imaging measurements.
Eur J Radiol Volume: 132 Page(s): 109307
11/01/2020 Authors: Higgins MI; Martini DJ; Patil DH; Steele S; Evans S; Petrinec BP; Psutka SP; Sekhar A; Bilen MA; Master VA -
Bladder Preserving Chemoradiotherapy Compared To Surgery For Variants Of Urothelial Carcinoma And Tumors With Divergent Differentiation: An Analysis Of The National Cancer Database
Volume: 108 Page(s): E887 - E888
11/01/2020 Authors: Janopaul-Naylor J; Zhong J; Liu Y; Zhang C; Osunkoya AO; Joshi SS; Bilen MA; Carthon B; Kucuk O; Hartsell LM -
EFFICACY OF SEQUENTIAL IMMUNE CHECKPOINT INHIBITION (ICI) IN PATIENTS WITH GENITOURINARY MALIGNANCIES
Volume: 8 Page(s): A154 - A155
11/01/2020 Authors: Evans S; Martini D; Magod B; Olsen T; Brown J; Yantorni L; Ravindranathan D; Russler G; Caulfield S; Goldman J -
BODY COMPOSITION MAY BE PROGNOSTIC AND PREDICTIVE OF CLINICAL OUTCOMES IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS (ICI)
Volume: 8 Page(s): A26 - A27
11/01/2020 Authors: Martini D; Olsen TA; Goyal S; Liu Y; Evans S; Magod B; Brown J; Yantorni L; Russler G; Caulfield S -
IMMUNE-RELATED ADVERSE EVENTS (IRAES) MAY INDICATE A FAVORABLE PROGNOSIS IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS (ICI)
Volume: 8 Page(s): A380 - A381
11/01/2020 Authors: Martini D; Evans S; Goyal S; Liu Y; Olsen TA; Magod B; Brown J; Yantorni L; Russler G; Caulfield S -
Phase 2 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses
Volume: 16 Page(s): 133 - 133
11/01/2020 Authors: Lee C-H; Shah AY; Hsieh JJ; Rao A; Pinto A; Bilen MA; Cohn AL; Di Simone C; Shaffer DR; Sarrio RG -
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma.
Br J Cancer Volume: 123 Page(s): 1228 - 1234
10/01/2020 Authors: Harvey RD; Carthon BC; Lewis C; Hossain MS; Zhang C; Chen Z; Harris WB; Alese OB; Shaib W; Bilen MA -
Sarcopenia and Neutrophil-Lymphocyte Ratio Are Associated with Overall Survival after Surgery for Localized Renal Cell Carcinoma
Volume: 231 Page(s): S339 - S339
10/01/2020 Authors: Higgins M; Nabavizadeh R; Patil DH; Ogan K; Kissick H; Bilen MA; Master V -
Considerations for cancer immunotherapy biomarker research during COVID-19.
Endocr Relat Cancer Volume: 27 Page(s): C1 - C8
09/01/2020 Authors: Carlisle JW; Jansen CS; Bilen MA; Kissick H -
Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
Oncologist Volume: 25 Page(s): 669 - 679
08/01/2020 Authors: Das S; Ciombor KK; Haraldsdottir S; Pumpalova Y; Sahin IH; Pineda G; Shyr Y; Lin EP; Hsu C-Y; Chu S-K -
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
Eur J Cancer Volume: 135 Page(s): 203 - 210
08/01/2020 Authors: McGregor BA; Lalani A-KA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV -
Dynamic Evaluation of the Modified Glasgow Prognostic Scale in Patients With Resected, Localized Clear Cell Renal Cell Carcinoma.
Volume: 141 Page(s): 101 - 107
07/01/2020 Authors: Patil D; Le T-L; Bens KB; Alemozaffar M; Lay A; Pattaras J; Filson CP; Ogan K; Bilen MA; Master VA -
Reply to Body fat indices and survival in immunotherapy-treated patients with cancer.
Cancer Volume: 126 Page(s): 3157 - 3159
07/01/2020 Authors: Martini DJ; Liu Y; Master VA; Harvey RD; Bilen MA -
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.
J Urol Volume: 204 Page(s): 63 - 70
07/01/2020 Authors: Miller NJ; Khaki AR; Diamantopoulos LN; Bilen MA; Santos V; Agarwal N; Morales-Barrera R; Devitt M; Nelson A; Hoimes CJ -
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Lancet Volume: 395 Page(s): 1907 - 1918
06/20/2020 Authors: Kuderer NM; Choueiri TK; Shah DP; Shyr Y; Rubinstein SM; Rivera DR; Shete S; Hsu C-Y; Desai A; de Lima Lopes G -
A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors.
Clin Cancer Res Volume: 26 Page(s): 2497 - 2505
06/01/2020 Authors: Owonikoko TK; Harvey RD; Carthon B; Chen Z; Lewis C; Collins H; Zhang C; Lawson DH; Alese OB; Bilen MA -
Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Volume: 38
05/20/2020 Authors: Pisick EP; Garrett-Mayer E; Halabi S; Mangat PK; Yang ES-H; Dib EG; Burgess EF; Zakem MH; Rohatgi N; Bilen MA -
Association of neutrophil to lymphocyte ratio (NLR) with efficacy from JAVELIN Renal 101.
Volume: 38
05/20/2020 Authors: Bilen MA; Rini B; Motzer RJ; Larkin JMG; Haanen JBAG; Albiges L; Pagliaro LC; Voog E; Lam ET; Kislov N -
Phase II study of nivolumab and ipilimumab for advanced rare genitourinary cancers.
Volume: 38
05/20/2020 Authors: McGregor BA; Campbell MT; Xie W; Farah S; Bilen MA; Sonpavde G; Kilbridge KL; Choudhury AD; Mortazavi A; Shah AY -
Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.
Volume: 38
05/20/2020 Authors: Mar N; Friedlander TW; Hoimes CJ; Flaig TW; Bilen MA; Balar AV; Henry E; Srinivas S; Rosenberg JE; Petrylak DP -
First-line PD-1/PD-L1 inhibitor monotherapy for advanced renal cell carcinoma (aRCC): A multi-institutional cohort.
Volume: 38
05/20/2020 Authors: Hatton W; Basu A; Koshkim VS; Kilari D; Jaeger E; Ledet EM; Cotogno P; Manogue C; Lewis BE; Layton JL -
In Reply.
Oncologist Volume: 25 Page(s): e876
05/01/2020 Authors: Bilen MA; Master VA; Harvey RD -
Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors.
Cancer Med Volume: 9 Page(s): 2752 - 2760
04/01/2020 Authors: Shabto JM; Martini DJ; Liu Y; Ravindranathan D; Brown J; Hitron EE; Russler GA; Caulfield S; Kissick H; Alemozaffar M -
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.
Cancer Volume: 126 Page(s): 1208 - 1216
03/15/2020 Authors: Khaki AR; Li A; Diamantopoulos LN; Bilen MA; Santos V; Esther J; Morales-Barrera R; Devitt M; Nelson A; Hoimes CJ -
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.
Oncologist Volume: 25 Page(s): e528 - e535
03/01/2020 Authors: Bilen MA; Martini DJ; Liu Y; Shabto JM; Brown JT; Williams M; Khan AI; Speak A; Lewis C; Collins H -
Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Oncologist Volume: 25 Page(s): e484 - e491
03/01/2020 Authors: Martini DJ; Liu Y; Shabto JM; Carthon BC; Hitron EE; Russler GA; Caulfield S; Kissick HT; Harris WB; Kucuk O -
Clinico-Pathologic Characteristics of Prostatic Adenocarcinoma Patients with Lymph Node Metastases
Volume: 33 Page(s): 938 - 939
03/01/2020 Authors: Monsrud A; Kline M; Speak A; Chen Z; Zhang Y; Bilen M; Harik L -
Clinico-Pathologic Characteristics of Prostatic Adenocarcinoma Patients with Lymph Node Metastases
Volume: 100 Page(s): 938 - 939
03/01/2020 Authors: Monsrud A; Kline M; Speak A; Chen Z; Zhang Y; Bilen M; Harik L -
Association of modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (CPI)
Volume: 38
02/20/2020 Authors: Brown JT; Liu Y; Martini DJ; Shabto JM; Hitron E; Russler G; Caulfield S; Yantorni LB; Joshi SS; Kissick H -
The real-world efficacy of abiraterone acetate (ABA) and docetaxel (DOC) in the treatment of African-American (AA) patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)
Volume: 38
02/20/2020 Authors: Smith KER; Brown JT; Liu Y; LaFollette JA; Moore MR; Bilen MA -
Association of baseline modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic urothelial cell carcinoma (mUCC) treated with immune checkpoint inhibitors (CPI)
Volume: 38
02/20/2020 Authors: Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron E; Russler G; Caulfield S; Yantorni LB; Joshi SS -
A risk scoring system for African-American (AA) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line abiraterone (ABA) or enzalutamide (ENZ)
Volume: 38
02/20/2020 Authors: Brown JT; Liu Y; LaFollette JA; Kucuk O; Moore MR; Bilen MA -
The role of 68Ga-DOTATATE for evaluation of patients with metastatic castration- resistant prostate cancer (mCRPC)
Volume: 38
02/20/2020 Authors: Bilen MA; Akintayo AA; Abiodun-Ojo OA; Kucuk O; Carthon BC; Schuster DM; Parent EE -
Real-world prognostic model for overall survival (OS) in patients (pts) with advanced urothelial cancer (aUC) treated with immune checkpoint inhibitors (ICI)
Volume: 38
02/20/2020 Authors: Khaki AR; Diamantopoulos LN; Miller NJ; Bilen MA; Santos VS; Morales-Barrera R; Devitt ME; Nelson AA; Shreck E; Assi H -
PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC)
Volume: 38
02/20/2020 Authors: Huddart RA; Siefker-Radtke AO; Balar AV; Bilen MA; Powles T; Bamias A; Castellano D; Khalil MF; Van der Heijden MS; Koshkin VS -
Circulating tumor (ct) DNA-based comprehensive genomic profiling to identify microsatellite instability (MSI) and defective DNA damage repair (DDR) in prostate cancer (PCa) patients
Volume: 38
02/20/2020 Authors: Drusbosky LM; Kiedrowski LA; Johnson K; Nagy R; Saam J; Bilen MA; Gupta NK; Lilly MB -
Outcomes of adult urogenital sarcomas: Analysis of surveillance, epidemiology, and end results (SEER) database 2004 to 2015
Volume: 38
02/20/2020 Authors: Nutalapati S; Chen Q; Huang B; Patel RA; Bilen MA; Myint Z -
Histologic subtype and response to immune checkpoint inhibitor (ICI) therapy in advanced urothelial cancer (aUC)
Volume: 38
02/20/2020 Authors: Miller NJ; Khaki AR; Diamantopoulos LN; Bilen MA; Santos VS; Morales-Barrera R; Devitt ME; Nelson AA; Shreck E; Assi H -
Clinical activity of BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: updated results from the phase 1/2 PIVOT-02 study
Volume: 18
02/11/2020 Authors: Diab A; Puzanov I; Maio M; Curti B; Bilen M; Lewis K; Tykodi S; Daniels G; Spira A; Bernatchez C -
Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials.
Cancer Volume: 126 Page(s): 575 - 582
02/01/2020 Authors: Martini DJ; Kline MR; Liu Y; Shabto JM; Williams MA; Khan AI; Lewis C; Collins H; Akce M; Kissick HT -
Multidisciplinary Care of Adult Wilms' Tumor During Pregnancy: A Case Report and Review of the Literature.
Clin Genitourin Cancer Volume: 18 Page(s): e1 - e4
02/01/2020 Authors: Brown JT; Harik LR; Barbee MS; Esiashvili N; Badell ML; Goldsmith KC; Master VA; Bilen MA -
Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
J Immunother Cancer Volume: 8
02/01/2020 Authors: Abou Alaiwi S; Xie W; Nassar AH; Dudani S; Martini D; Bakouny Z; Steinharter JA; Nuzzo PV; Flippot R; Martinez-Chanza N -
The impact of inflammatory biomarkers, BMI, and sarcopenia on survival in advanced hepatocellular carcinoma treated with immunotherapy
Volume: 38
02/01/2020 Authors: Akce M; Liu Y; Zakka KM; Martini DJ; Draper A; Alese OB; Shaib WL; Wu C; Wedd J; Sellers MT -
Ramucirumab and Docetaxel in Patients with Metastatic Urothelial Carcinoma Harboring Fibroblast Growth Factor Receptor Alterations: A Case Series and Literature Review.
J Immunother Precis Oncol Volume: 3 Page(s): 23 - 26
02/01/2020 Authors: Smith KER; Hitron EE; Russler GA; Baumgarten DA; Bilen MA -
Nonbacterial Thrombotic Endocarditis and Widespread Skin Necrosis in Newly Diagnosed Lung Adenocarcinoma.
Case Rep Oncol Volume: 13 Page(s): 239 - 244
01/01/2020 Authors: Zakka K; Zakka P; Davarpanah A; Koshkelashvili N; Bilen MA; Owonikoko T; El-Rayes B; Akce M -
Current Landscape of Immunotherapy in Genitourinary Malignancies.
Adv Exp Med Biol Volume: 1244 Page(s): 107 - 147
01/01/2020 Authors: Alhalabi O; Rafei H; Bilen MA; Shah AY -
Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort.
Front Oncol Volume: 10 Page(s): 581189
01/01/2020 Authors: Barata P; Hatton W; Desai A; Koshkin V; Jaeger E; Manogue C; Cotogno P; Light M; Lewis B; Layton J -
Immunotherapy in sarcomatoid renal cell carcinoma: A case for optimism.
Cancer Treat Res Commun Volume: 25 Page(s): 100257
01/01/2020 Authors: Brown JT; Bilen MA -
Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report.
Front Oncol Volume: 10 Page(s): 622134
01/01/2020 Authors: Bilen MA; Jiang JF; Jansen CS; Brown JT; Harik LR; Sekhar A; Kissick H; Maithel SK; Kucuk O; Carthon B -
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.
Oncologist
12/05/2019 Authors: Bilen MA; Martini DJ; Liu Y; Shabto JM; Brown JT; Williams M; Khan AI; Speak A; Lewis C; Collins H -
Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Oncologist
12/05/2019 Authors: Martini DJ; Liu Y; Shabto JM; Carthon BC; Hitron EE; Russler GA; Caulfield S; Kissick HT; Harris WB; Kucuk O -
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.
Invest New Drugs Volume: 37 Page(s): 1198 - 1206
12/01/2019 Authors: Martini DJ; Liu Y; Shabto JM; Lewis C; Kline MR; Collins H; Akce M; Kissick HT; Carthon BC; Shaib WL -
An intra-tumoral niche maintains and differentiates stem-like CD8 T cells.
Nature Volume: 576 Page(s): 465 - 470
12/01/2019 Authors: Jansen CS; Prokhnevska N; Master VA; Sanda MG; Carlisle JW; Bilen MA; Cardenas M; Wilkinson S; Lake R; Sowalsky AG -
Clinical activity of BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: updated results from the phase 1/2 PIVOT-02 study
Volume: 7
11/06/2019 Authors: Diab A; Puzanov I; Maio M; Curti B; Bilen M; Lewis K; Tykodi S; Daniels G; Spira A; Bernatchez C -
A Review of Papillary Renal Cell Carcinoma and MET Inhibitors.
Kidney Cancer Volume: 3 Page(s): 151 - 161
11/01/2019 Authors: Rhoades Smith KE; Bilen MA -
Hybrid negative enrichment of circulating tumor cells from whole blood in a 3D-printed monolithic device.
Lab Chip Volume: 19 Page(s): 3427 - 3437
10/09/2019 Authors: Chu C-H; Liu R; Ozkaya-Ahmadov T; Boya M; Swain BE; Owens JM; Burentugs E; Bilen MA; McDonald JF; Sarioglu AF -
Initial results of a phase II study of nivolumab and ipilimumab in metastatic adrenal tumours
Volume: 30 Page(s): 400 - 400
10/01/2019 Authors: Campbell MT; Xie W; Shah AY; Habra MA; Jimenez C; Venkatesan AM; Bubley G; McKay RR; Choueiri TK; McGregor BA -
Variation in Estimated Glomerular Filtration Rate Values Before Nephrectomy Based on Cystatin C, Chronic Kidney Disease Epidemiology Collaboration, Cockcroft-Gault, and Modification of Diet in Renal Disease Formulas
Volume: 229 Page(s): S323 - S323
10/01/2019 Authors: Hong G; Henry M; Pirani F; Patil D; Ogan K; Connor M; Bilen MA; Harvey RD; Bryksin J; Master V -
Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab plus axitinib (A plus Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)
Volume: 30
10/01/2019 Authors: Albiges L; Rini BI; Haanen JBAG; Motzer RJ; Kollmannsberger CK; Negrier S; Nole F; Bedke J; Bilen MA; Nathan P -
Management of metastatic renal cell carcinoma: The complexity of choice.
EBioMedicine Volume: 47 Page(s): 2 - 3
09/01/2019 Authors: Brown JT; Bilen MA -
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy.
BMC Cancer Volume: 19 Page(s): 857
08/29/2019 Authors: Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL -
MRI quantitation of abdominal skeletal muscle correlates with CT-based analysis: implications for sarcopenia measurement.
Appl Physiol Nutr Metab Volume: 44 Page(s): 814 - 819
08/01/2019 Authors: Khan AI; Reiter DA; Sekhar A; Sharma P; Safdar NM; Patil DH; Psutka SP; Small WC; Bilen MA; Ogan K -
CD8 T-cell infiltration into renal tumors requires a supportive antigen-presenting niche
Volume: 79
07/01/2019 Authors: Jansen CS; Prokhnevska N; Master VA; Carlisle JW; Bilen MA; Reyes AM; Kissick HT -
The role of dopamine signaling in prostate cancer disparities
Volume: 79
07/01/2019 Authors: Pickett IR; Boston AM; Almathkour MM; Ragin C; Bilen MA; Osunkoya AO; Cinar B -
Reply to Tumor-associated macrophages: "Good cop-bad cop".
Cancer Volume: 125 Page(s): 1942 - 1943
06/01/2019 Authors: Bilen MA; Kissick HT; Harvey RD -
Novel risk stratification criteria of metastatic renal cell carcinoma (mRCC) patients (pts) treated with immune checkpoint inhibitors (ICI).
Volume: 37
05/20/2019 Authors: Martini DJ; Liu Y; Shabto JM; Carthon BC; Russler G; Hitron E; Caulfield S; Kissick H; Harris W; Kucuk O -
First-line PD(L)1 inhibitors for platinum-ineligible advanced urothelial carcinoma (aUC).
Volume: 37
05/20/2019 Authors: Agarwal A; Pond GR; Gupta R; Ornstein MC; Barata PC; Garcia JA; Drakaki A; Lee J-L; Kanesvaran R; Bilen MA -
Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
Cancer Volume: 125 Page(s): 1459 - 1469
05/01/2019 Authors: Sonpavde G; Agarwal N; Pond GR; Nagy RJ; Nussenzveig RH; Hahn AW; Sartor O; Gourdin TS; Nandagopal L; Ledet EM -
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
Lancet Oncol Volume: 20 Page(s): 581 - 590
04/01/2019 Authors: Martnez Chanz N; Xie W; Asim Bilen M; Dzimitrowicz H; Burkart J; Geynisman DM; Balakrishnan A; Bowman IA; Jain R; Stadler W -
Analysis of toxicity and clinical outcomes (CO) in full versus reduced dose cabozantinib (cabo) in metastatic renal cell carcinoma (mRCC) patients (pts).
Volume: 37
03/01/2019 Authors: Martini DJ; Shabto JM; Liu Y; Carthon BC; Speak A; Hitron E; Russler G; Caulfield S; Ogan K; Harris W -
Association of inflammation and clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).
Volume: 37
03/01/2019 Authors: Martini DJ; Shabto JM; Liu Y; Carthon BC; Speak A; Hitron E; Russler G; Caulfield S; Ogan K; Harris W -
Sites of metastases (mets) and their association with clinical outcomes (CO) in urothelial cancer patients (pts) treated with immunotherapy (IO).
Volume: 37
03/01/2019 Authors: Shabto JM; Martini DJ; Liu Y; Ravindranathan D; Kline MR; Hitron E; Russler G; Caulfield S; Kissick H; Alemozaffar M -
Association between immune-related adverse events (irAEs) and clinical outcomes (CO) in advanced urothelial cancer patients (pts) treated with immunotherapy (IO).
Volume: 37
03/01/2019 Authors: Shabto JM; Martini DJ; Liu Y; Ravindranathan D; Kline MR; Hitron E; Russler G; Caulfield S; Kissick H; Alemozaffar M -
Inflammatory markers at baseline (C1) and cycle 3 (C3) and their association with clinical outcomes in urothelial cancer patients (pts) treated with immunotherapy (IO).
Volume: 37
03/01/2019 Authors: Shabto JM; Martini DJ; Liu Y; Ravindranathan D; Kline MR; Hitron E; Russler G; Caulfield S; Kissick H; Alemozaffar M -
Body mass index (BMI) and toxicities and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).
Volume: 37
03/01/2019 Authors: Martini DJ; Shabto JM; Liu Y; Carthon BC; Speak A; Hitron E; Russler G; Caulfield S; Ogan K; Harris W -
Sites of metastasis (mets) and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).
Volume: 37
03/01/2019 Authors: Martini DJ; Shabto JM; Liu Y; Carthon BC; Speak A; Hitron E; Russler G; Caulfield S; Ogan K; Harris W -
Sarcopenia is independently associated with decreased overall survival after surgery for inferior vena cava tumor thrombus patients.
Volume: 37
03/01/2019 Authors: Williams M; Nabavizadeh R; Khan AI; Patil DH; Psutka SP; Sekhar A; Ogan K; Bilen MA; Master VA -
Safety and efficacy of restarting immune checkpoint inhibitors (CPI) after immune-related adverse events (irAEs) in metastatic renal cell carcinoma (mRCC).
Volume: 37
03/01/2019 Authors: Abou Alaiwi S; Martini DJ; Xie W; Nassar A; Bakouny Z; Steinharter JA; Nuzzo PV; Flippot R; Chanza NM; Wei XX -
Sequential immunotherapy and association with clinical outcomes in advanced-stage cancer patients
Volume: 7
02/01/2019 Authors: Bilen M; Martini D; Liu Y; Lewis C; Collins H; Shabto J; Akce M; Kissick H; Carthon B; Shaib W -
Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic Stage IV melanoma
Volume: 17
01/15/2019 Authors: Diab A; Tykodi S; Curti B; Cho D; Wong M; Puzanov I; Lewis K; Maio M; Daniels GA; Spira A -
Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation.
Volume: 42 Page(s): 36 - 41
01/01/2019 Authors: Zhong J; Switchenko J; Jegadeesh NK; Cassidy RJ; Gillespie TW; Master V; Nieh P; Alemozaffar M; Kucuk O; Carthon B -
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.
Cancer Volume: 125 Page(s): 127 - 134
01/01/2019 Authors: Bilen MA; Martini DJ; Liu Y; Lewis C; Collins HH; Shabto JM; Akce M; Kissick HT; Carthon BC; Shaib WL -
Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders.
J Immunother Cancer Volume: 6 Page(s): 159
12/27/2018 Authors: Boilve A; Carlo MI; Barthlmy P; Oudard S; Borchiellini D; Voss MH; George S; Chevreau C; Landman-Parker J; Tabone M-D -
The addition of chemotherapy in the definitive management of high risk prostate cancer.
Urol Oncol Volume: 36 Page(s): 475 - 487
11/01/2018 Authors: Ferris MJ; Liu Y; Ao J; Zhong J; Abugideiri M; Gillespie TW; Carthon BC; Bilen MA; Kucuk O; Jani AB -
Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
Eur J Cancer Volume: 104 Page(s): 188 - 194
11/01/2018 Authors: Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM -
New Preoperative Inflammatory Score Is an Independent and Significant Predictor of Overall Survival in Localized Clear Cell Renal Cell Carcinoma
Volume: 227 Page(s): E244 - E244
10/01/2018 Authors: Melnick KR; Khan AI; Patil D; Kim F; Patel AP; Bilen MA; Kucuk O; Filson CP; Ogan K; Master V -
High Preoperative Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival in Localized and Metastatic Clear Cell Renal Cell Carcinoma
Volume: 227 Page(s): E243 - E243
10/01/2018 Authors: Khan AI; Melnick KR; Patil D; Kim F; Laganosky DD; Bilen MA; Kucuk O; Filson CP; Ogan K; Master V -
Serial Measurements of C-Reactive Protein: Albumin Ratio Can Stratify Risk and Survival in Patients with Clear Cell Renal Cell Carcinoma
Volume: 227 Page(s): E245 - E245
10/01/2018 Authors: Laganosky DD; Khan AI; Patil D; Lay AH; Pattaras JG; Bilen MA; Kucuk O; Ogan K; Master V -
Sarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO).
Volume: 29 Suppl 8 Page(s): viii42
10/01/2018 Authors: Bilen MA; Martini DJ; Shabto JM; Liu Y; Khan AI; Williams MA; Lewis C; Collins HH; Kissick H; Carthon BC -
Sites of metastasis and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO).
Ann Oncol Volume: 29 Suppl 8 Page(s): viii433
10/01/2018 Authors: Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins HH; Akce M; Kissick H; Carthon BC; Shaib WL -
Therapeutic Vaccines for Genitourinary Malignancies.
Vaccines (Basel) Volume: 6
08/12/2018 Authors: Dutcher GMA; Bilen MA -
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.
Invest New Drugs Volume: 36 Page(s): 638 - 646
08/01/2018 Authors: Fujii T; Colen RR; Bilen MA; Hess KR; Hajjar J; Suarez-Almazor ME; Alshawa A; Hong DS; Tsimberidou A; Janku F -
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept.
Invest New Drugs Volume: 36 Page(s): 601 - 607
08/01/2018 Authors: Colen RR; Fujii T; Bilen MA; Kotrotsou A; Abrol S; Hess KR; Hajjar J; Suarez-Almazor ME; Alshawa A; Hong DS -
Blood based biomarkers and association with clinical outcome (CO) in advanced stage patients (pts) treated with immunotherapy (IO)
Volume: 78
07/01/2018 Authors: Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Pillai R -
Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab.
Clin Genitourin Cancer Volume: 16 Page(s): e563 - e575
06/01/2018 Authors: Bilen MA; Dutcher GMA; Liu Y; Ravindranathan D; Kissick HT; Carthon BC; Kucuk O; Harris WB; Master VA -
Early change in blood-based biomarkers and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO)
Volume: 36
05/20/2018 Authors: Martini DJ; Liu Y; Lewis CM; Shabto JM; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Pillai RN -
Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
Cancer Volume: 124 Page(s): 2115 - 2124
05/15/2018 Authors: Agarwal N; Pal SK; Hahn AW; Nussenzveig RH; Pond GR; Gupta SV; Wang J; Bilen MA; Naik G; Ghatalia P -
Validation of a novel preoperative inflammatory score in localized, clear cell RCC.
Volume: 36
02/20/2018 Authors: Melnick KR; Patil DH; Khan AI; Kim FY; Bilen MA; Carthon BC; Kucuk O; Filson CP; Ogan K; Kissick HT -
Evaluation of preoperative C-reactive protein: Albumin ratio in patients with clear cell renal cell carcinoma.
Volume: 36
02/20/2018 Authors: Patil DH; Williams S; Torlak M; Alemozaffar M; Lay A; Pattaras J; Kucuk O; Carthon BC; Bilen MA; Ogan K -
Single center validation of neutrophil-to-lymphocyte ratio in localized and metastatic clear cell renal cell carcinoma.
Volume: 36
02/20/2018 Authors: Melnick KR; Patil DH; Khan AI; Kim FY; Torlak M; Bilen MA; Kucuk O; Carthon BC; Filson CP; Ogan K -
Immunologic profile and prognostic significance of tumor-infiltrating lymphocytes in renal cell carcinoma.
Volume: 36
02/20/2018 Authors: Khan AI; Jansen CS; Carlisle JW; Melnick KR; Kim KS; Hosseinzadeh F; Prokhnevska N; Bilen MA; Master VA; Kissick HT -
The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma.
Expert Opin Investig Drugs Volume: 27 Page(s): 163 - 170
02/01/2018 Authors: Bilen MA; Carlisle JW; Sonpavde G -
Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma.
Oncoimmunology Volume: 7 Page(s): e1413519
01/01/2018 Authors: Kim KS; Sekar RR; Patil D; Dimarco MA; Kissick HT; Bilen MA; Osunkoya AO; Master VA -
Metastatic Prostate Cancer Manifesting as Cholestatic Jaundice: A Case Report and Review of the Literature.
Case Rep Oncol Med Volume: 2018 Page(s): 1809432
01/01/2018 Authors: Ravindranathan D; Hitron EE; Russler GA; Xue Y; Bilen MA -
A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma.
Asian J Urol Volume: 4 Page(s): 230 - 238
10/01/2017 Authors: Sekar RR; Patil D; Baum Y; Pearl J; Bausum A; Bilen MA; Kucuk O; Harris WB; Carthon BC; Alemozaffar M -
Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology.
CA Cancer J Clin Volume: 67 Page(s): 362 - 377
09/01/2017 Authors: Ethun CG; Bilen MA; Jani AB; Maithel SK; Ogan K; Master VA -
Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy.
Cancer Chemother Pharmacol Volume: 80 Page(s): 583 - 589
09/01/2017 Authors: Bilen MA; Hess KR; Subudhi SK; Aparicio A; Kim J; Zurita-Saavedra AJ; Araujo JC; Corn PG; Stover J; Lin S-H -
Immune checkpoint inhibitors following targeted therapies in MITF family translocation renal cell carcinomas
Volume: 28
09/01/2017 Authors: Boileve A; Carlo M; Barthelemy P; Oudard S; Borchiellini D; Voss M; George S; Chevreau C; Landman-Parker J; Tabone M-D -
Cabozantinib for the treatment of patients with metastatic variant histology renal cell carcinoma (vhRCC): a retrospective study
Volume: 28
09/01/2017 Authors: Campbell MT; Bilen MA; Duran C; Altinmakas E; Lim Z; Shah A; Jonasch E; Tannir N -
Proteomics Profiling of Exosomes from Primary Mouse Osteoblasts under Proliferation versus Mineralization Conditions and Characterization of Their Uptake into Prostate Cancer Cells.
J Proteome Res Volume: 16 Page(s): 2709 - 2728
08/04/2017 Authors: Bilen MA; Pan T; Lee Y-C; Lin S-C; Yu G; Pan J; Hawke D; Pan B-F; Vykoukal J; Gray K -
Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin.
Clin Genitourin Cancer Volume: 15 Page(s): e429 - e435
06/01/2017 Authors: Bilen MA; Cauley DH; Atkinson BJ; Chen H-C; Kaya DH; Wang X; Vikram R; Tu S-M; Corn PG; Kim J -
Recent developments in the management of germ cell tumors.
Curr Opin Oncol Volume: 29 Page(s): 172 - 178
05/01/2017 Authors: Msaouel P; Bilen MA; Zhang M; Campbell M; Wang J; Tu S-M -
Retrospective review of cytotoxic chemotherapy and anti-angiogenic combinations in renal cell carcinoma: A single institution experience.
Volume: 35
02/20/2017 Authors: Carthon BC; Tabba M; Ellis C; Harris W; Bilen MA; Canter D -
Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis.
Oncotarget Volume: 7 Page(s): 86280 - 86289
12/27/2016 Authors: Bilen MA; Hess KR; Campbell MT; Wang J; Broaddus RR; Karam JA; Ward JF; Wood CG; Choi SL; Rao P -
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials.
Cancer Chemother Pharmacol Volume: 78 Page(s): 167 - 171
07/01/2016 Authors: Bilen MA; Patel A; Hess KR; Munoz J; Busaidy NL; Wheler JJ; Janku F; Falchook GS; Hong DS; Meric-Bernstam F -
Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer.
Cancer Volume: 122 Page(s): 1836 - 1843
06/15/2016 Authors: Tu S-M; Bilen MA; Hess KR; Broaddus RR; Kopetz S; Wei C; Pagliaro LC; Karam JA; Ward JF; Wood CG -
Personalised cancer care: promises and challenges of targeted therapy.
J R Soc Med Volume: 109 Page(s): 98 - 105
03/01/2016 Authors: Tu S-M; Bilen MA; Tannir NM -
Cadherin-11 endocytosis through binding to clathrin promotes cadherin-11-mediated migration in prostate cancer cells.
J Cell Sci Volume: 128 Page(s): 4629 - 4641
12/15/2015 Authors: Satcher RL; Pan T; Bilen MA; Li X; Lee Y-C; Ortiz A; Kowalczyk AP; Yu-Lee L-Y; Lin S-H -
Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.
Oncologist Volume: 20 Page(s): 1140 - 1148
10/01/2015 Authors: Bilen MA; Zurita AJ; Ilias-Khan NA; Chen H-C; Wang X; Kearney AY; Hodges S; Jonasch E; Huang S; Khakoo AY -
Radium-223: Optimizing Treatment and Research of Osteoblastic Bone Metastasis.
Oncology (Williston Park) Volume: 29 Page(s): 490 - 492
07/01/2015 Authors: Tu S-M; Bilen MA; Lin S-H -
Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.
Cancer Chemother Pharmacol Volume: 75 Page(s): 869 - 874
04/01/2015 Authors: Bilen MA; Fu S; Falchook GS; Ng CS; Wheler JJ; Abdelrahim M; Erguvan-Dogan B; Hong DS; Tsimberidou AM; Kurzrock R -
Angiomotin is a novel component of cadherin-11/-catenin/p120 complex and is critical for cadherin-11-mediated cell migration.
FASEB J Volume: 29 Page(s): 1080 - 1091
03/01/2015 Authors: Ortiz A; Lee Y-C; Yu G; Liu H-C; Lin S-C; Bilen MA; Cho H; Yu-Lee L-Y; Lin S-H -
Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer.
Cancer Volume: 121 Page(s): 69 - 76
01/01/2015 Authors: Bilen MA; Johnson MM; Mathew P; Pagliaro LC; Araujo JC; Aparicio A; Corn PG; Tannir NM; Wong FC; Fisch MJ -
Variant prostate carcinoma and elevated serum CA-125.
Can J Urol Volume: 21 Page(s): 7442 - 7448
10/01/2014 Authors: Bilen MA; Reyes A; Bhowmick D; Maa A; Bast R; Pisters LL; Lin S-H; Logothetis CJ; Tu S-M -
The scientific method: pillar and pitfall of cancer research.
Cancer Med Volume: 3 Page(s): 1035 - 1037
08/01/2014 Authors: Tu S-M; Bilen MA; Tannir NM -
Positive FDG-PET/CT scans of a residual seminoma after chemotherapy and radiotherapy: case report and review of the literature.
Clin Genitourin Cancer Volume: 12 Page(s): e147 - e150
08/01/2014 Authors: Bilen MA; Hariri H; Leon C; Guo CC; Kuban DA; Pisters LL; Tu S-M -
Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy.
Invest New Drugs Volume: 32 Page(s): 717 - 722
08/01/2014 Authors: Bilen MA; Durand J-B; McQuinn L; Hess KR; Fu S; Falchook GS; Hong DS; Wheler JJ; Said R; Ewer MS -
Inhibition of cell adhesion by a cadherin-11 antibody thwarts bone metastasis.
Mol Cancer Res Volume: 11 Page(s): 1401 - 1411
11/01/2013 Authors: Lee Y-C; Bilen MA; Yu G; Lin S-C; Huang C-F; Ortiz A; Cho H; Song JH; Satcher RL; Kuang J -
Cixutumumab-associated pancolitis in a patient with prostate cancer.
Clin Genitourin Cancer Volume: 11 Page(s): 207 - 210
06/01/2013 Authors: Bilen MA; Kim J; Wang H; Tu S-M -
Pathologic complete response in poorly differentiated adenocarcinomas of the appendix: a case series.
Acta Oncol Volume: 52 Page(s): 1044 - 1046
06/01/2013 Authors: Bilen MA; Taggart MW; Fournier K; Ellis LM; Mansfield PF; Eng C; Royal RE; Overman MJ -
Allogenic stem cell transplant (ASCT) as initial salvage for patients (pts) with acute myeloid leukemia (AML) refractory to high-dose cytarabine-based induction chemotherapy
Volume: 30
05/20/2012 Authors: Daver NG; De Lima MJG; Kantarjian H; Ravandi F; Bilen MA; Pierce S; Khouri IF; Dorkhom SJ; Giralt S; Garcia-Manero G -
Prolonged remission of fulminant castrate-resistant prostate cancer: a case report.
Clin Genitourin Cancer Volume: 9 Page(s): 133 - 136
12/01/2011 Authors: Bilen MA; General R; Tu S-M -
Think Zebra: An Unusual Cause of Nausea, Vomiting, and Abdominal Pain
Volume: 106 Page(s): S192 - S193
10/01/2011 Authors: Bilen M; Yilmaz E; Bilen O; Sulak L; Lu L; Hughes J -
BMP4 promotes prostate tumor growth in bone through osteogenesis.
Cancer Res Volume: 71 Page(s): 5194 - 5203
08/01/2011 Authors: Lee Y-C; Cheng C-J; Bilen MA; Lu J-F; Satcher RL; Yu-Lee L-Y; Gallick GE; Maity SN; Lin S-H -
Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts.
Cancer Res Volume: 70 Page(s): 4580 - 4589
06/01/2010 Authors: Huang C-F; Lira C; Chu K; Bilen MA; Lee Y-C; Ye X; Kim SM; Ortiz A; Wu F-LL; Logothetis CJ -
Androgen depletion up-regulates cadherin-11 expression in prostate cancer.
J Pathol Volume: 221 Page(s): 68 - 76
05/01/2010 Authors: Lee Y-C; Cheng C-J; Huang M; Bilen MA; Ye X; Navone NM; Chu K; Kao H-H; Yu-Lee L-Y; Wang Z -
Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy.
Cancer Volume: 115 Page(s): 2872 - 2880
07/01/2009 Authors: Tu S-M; Lopez A; Leibovici D; Bilen MA; Evliyaoglu F; Aparicio A; Guo CC; Kuban DA; Johnson MM; Pisters LL -
Modulation of prostate cancer cell gene expression by cell-to-cell contact with bone marrow stromal cells or osteoblasts.
Clin Exp Metastasis Volume: 26 Page(s): 993 - 1004
01/01/2009 Authors: Zhang S; Wang J; Bilen MA; Lin S-H; Stupp SI; Satcher RL -
Multisystem crisis in a patient with presumptive renal cell carcinoma.
Clin Genitourin Cancer Volume: 6 Page(s): 128 - 130
09/01/2008 Authors: Bilen MA; Waguespack SG; Tannir NM; Pravinkumar SE; Tamboli P; Tu S-M